RxDoctor Payments Data

Sakshi Kaul, MD

Pain Medicine · Saint Cloud, MNNPI 1184044067

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,499 of the $5,359 with a category attached, or 65.3%. 8 manufacturers reported payments, led by Nevro Corp. at 28.8% of the total.

$5,359in general payments, 2019–2025

Across 57 payments — averaging $94.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Stryker$1K
  • Si-bone, Inc.$871
  • Boston Scientific$861
  • Abbott$666
  • Medtronic$357
  • plus $26 from 2 others

What the payments were for

  • Travel & lodging$3,49965%
  • Food & beverage$1,82034%
  • Education$401%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nevro Corp.15$1,542
Stryker6$1,036
Si-bone, Inc.7$871
Boston Scientific5$861
Abbott14$666
Medtronic(2 entities)8$357
Collegium Pharmaceutical, Inc.1$13
Biogen1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,359 in reported general payments places this provider in the 70th percentile of 88 pain medicine providers in Minnesota.

See all pain medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$142,549
Medicare patients
296
Services billed
8,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl22$13,276
SavellaMilnacipran Hcl12$11,455
Pregabalin221$6,394
Duloxetine Hcl160$4,493
Buprenorphine12$4,208
Gabapentin68$1,837
Lacosamide19$1,466
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$1,460
Metaxalone11$991
Methocarbamol47$824
Tizanidine Hcl63$638
AmantadineAmantadine Hcl40$594
Oxycodone Hcl35$463
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$451
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$13$13,27622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 pain medicine providers in Minnesota.

Other pain medicine in Saint Cloud

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →